The Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX) is evaluating the efficacy and safety of CBD transdermal gel (ZYN002) in children ages three through 17 years with Fragile X Syndrome. There is currently no therapeutic option approved for the treatment of behavioral symptoms associated with FXS. CONNECT-FX is enrolling eligible patients to help researchers find a potential treatment for these patients and their families.
ZYN002 is an experimental treatment. This means that it is not approved by government regulatory bodies, including the United States Food and Drug Administration (FDA) and other agencies and must be tested to see if it is an effective and safe treatment.
For more information on this clinical trial, click the picture below.
For more information about any of our U.S. clinical studies or study site locations, go to https://clinicaltrials.gov.